Artículo
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, Carlos Maximiliano
; Grotz, Estefanía
; Bernabeu, Ezequiel Adrian
; Moretton, Marcela Analía
; Chiappetta, Diego Andrés
Fecha de publicación:
02/2017
Editorial:
Elsevier
Revista:
Drug Discovery Today
ISSN:
1359-6446
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer–drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics.
Palabras clave:
Cancer
,
Doxorubicin
,
Nanotechnological Formulations
,
Passive Targeting
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(OCA HOUSSAY)
Articulos de OFICINA DE COORDINACION ADMINISTRATIVA HOUSSAY
Articulos de OFICINA DE COORDINACION ADMINISTRATIVA HOUSSAY
Citación
Cagel, Carlos Maximiliano; Grotz, Estefanía; Bernabeu, Ezequiel Adrian; Moretton, Marcela Analía; Chiappetta, Diego Andrés; Doxorubicin: nanotechnological overviews from bench to bedside; Elsevier; Drug Discovery Today; 22; 2; 2-2017; 270-281
Compartir
Altmétricas